Intellia Therapeutics, Inc.
롱
업데이트됨

NTLA - Inverse head & shoulders

175
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.

Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
노트
Note: 2 other companies also developing CRISPR-Cas9 tech are CRSP and EDIT. Their stocks have skyrocketed the past month. It is advisable to wait for a correction before taking a position on them.
거래청산: 타겟 닿음
It wasn't a straightforward journey, but got there on time anyway! I hope everyone reading took profits at $31 (or even higher)

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.